Rexahn Pharmaceuticals Enrolls 100 Patients in Serdaxin Phase IIb Clinical Trial for Depression

PipelineReview.com, 23 Mar 2011

Rexahn Pharmaceuticals announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD)

ROCKVILLE, MD, USA | March 23, 2011 | Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD). The study calls for enrollment of up to 300 patients and is being conducted at approximately 40 sites in the United States. Enrollment for the Phase IIb trial was initiated in January 2011.

“We are pleased with the rapid progress we are making in Serdaxin’s Phase IIb trial enrollment,” said Rick Soni, President of Rexahn. “We remain on track to complete enrollment in the first half of 2011, with preliminary results expected in late 2011.”

The Serdaxin Phase IIb clinical trial is designed as a randomized, double blind, placebo-controlled study with three treatment arms. The primary endpoint is the change from baseline on the Montgomery-Asberg Depression Rating Scale (“MADRS”).

Phase IIa completed. Phase IIb is beginning recruitment. See locations in this link for Phase IIa.